

Current and Future Integration of Antibody-Drug Conjugates into the Management of Metastatic Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following outcomes was observed in the Phase III ASCENT-04/KEYNOTE-D19 trial among patients who received first-line sacituzumab govitecan with pembrolizumab compared to chemotherapy with pembrolizumab for PD-L1-positive metastatic triple-negative breast cancer (mTNBC)?
 - a. Inferior progression-free survival (PFS) with sacituzumab/pembrolizumab
 - b. Numerical but nonsignificant improvement in median PFS with sacituzumab/pembrolizumab
 - c. Statistically significant improvement in median PFS with sacituzumab/pembrolizumab
2. Emerging findings from the Phase III ASCENT-03 study evaluating first-line sacituzumab govitecan versus chemotherapy for patients with mTNBC who are not candidates for PD-1/PD-L1 inhibitors include which of the following outcomes?
 - a. Inferior PFS with sacituzumab govitecan
 - b. Numerical but nonsignificant improvement in PFS with sacituzumab govitecan
 - c. Statistically significant improvement in PFS with sacituzumab govitecan
3. Which of the following antibody-drug conjugates demonstrated an overall survival (OS) benefit in comparison to chemotherapy for relapsed/refractory advanced HR-positive, HER2-negative breast cancer?
 - a. Datopotamab deruxtecan
 - b. Sacituzumab govitecan
 - c. Both a and b
 - d. Neither a nor b
4. Emerging data from the Phase III DESTINY-Breast11 study comparing trastuzumab deruxtecan (T-DXd) followed by docetaxel/trastuzumab/pertuzumab (THP) before surgery to standard neoadjuvant therapy for high-risk HER2-positive localized breast cancer report which efficacy finding?
 - a. A numerical but nonsignificant improvement in pathologic complete response (pCR) rate with T-DXd followed by THP
 - b. A statistically significant improvement in pCR rate with T-DXd followed by THP
 - c. A numerical but nonsignificant improvement in OS with T-DXd followed by THP
 - d. A statistically significant improvement in OS with T-DXd followed by THP
5. What was the reported hazard ratio for PFS in the Phase III ASCENT-04/KEYNOTE-D19 trial evaluating first-line sacituzumab govitecan with pembrolizumab versus chemotherapy with pembrolizumab for patients with PD-L1-positive mTNBC?
 - a. 0.30
 - b. 0.65
 - c. 0.90